Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Recurrent Solid Tumors: early-phase trial registry

1 of 2 indexed Recurrent Solid Tumors trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #7,188 of 28,707 conditions by registered trial count.

2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count

Recurrent Solid Tumors: 2 US clinical trials tracked, 1 recruiting.

Recurrent Solid Tumors is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Immatics US, running 1 of these trials.

Enrollment posture brief

Registry condition recurrent-solid-tumors

OPEN 1 | RECR 50% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1

Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Recurrent Solid Tumors (this)50%
Open-enrollment share among volume-matched conditions near Recurrent Solid Tumors

Recurrent Solid Tumors lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Recurrent Solid Tumors on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Recurrent Solid Tumors is recruiting above its size-band peers.

    1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 12

Phase Distribution

PhaseTrial count
Phase 1 2

Top Sponsors

Immatics US 1 trials
Genentech 1 trials

Named interventions

Most-linked intervention names on Recurrent Solid Tumors records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

IMADetect® Diagnostic test
1 trials
IMA201 Product Biological
1 trials
RO7566802 Drug
1 trials
Atezolizumab Drug
1 trials

US sites by state

Facility locations filed on Recurrent Solid Tumors trials. A trial with sites in several states counts in each.

Pennsylvania 2 trials
Texas 1 trials
Tennessee 1 trials
Ohio 1 trials
New York 1 trials
Connecticut 1 trials
Alabama 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Recurrent Solid Tumors page

2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Recurrent Solid Tumors trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Immatics US sponsors the most Recurrent Solid Tumors trials on record, review their full trial history before evaluating a specific study. See Immatics US's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Solid Tumors condition card totals 2 registered trials; most-linked intervention IMADetect®; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.